Mike Patrone

Michael R. Patrone

Partner
Michael R. Patrone
New York
+1 212 459 7293

Michael Patrone is a partner in each of the firm’s Life Sciences and Private Equity business units, as well as a member of its Public M&A/Corporate Governance practice and Special Purpose Acquisition Companies (“SPAC”) practice. Michael’s practice focuses on all aspects of mergers and acquisitions, including representing both domestic and foreign entities, boards of directors, special board committees, private equity sponsors and investment banks in public and private company transactions, tender offers, joint ventures, reverse mergers, transactions with SPACs, cross-border transactions, minority investments, shareholder activism and governance disputes, financial advisory matters, and general corporate matters. Michael represents a wide range of clients from a number of industries, including life sciences, biotech, pharmaceuticals, regenerative medicine, technology, software, healthcare, financial services, and telecommunications.

Experience

A selection of Michael’s recent representations include:

  • MyoKardia, Inc. in connection with its $13.1 billion sale to Bristol-Myers Squibb Company
  • Biocon Biologics Limited in connection with its pending acquisition of Viatris Inc.’s biosimilars business for cash and stock valued at approximately $3.335 billion
  • Twilio Inc. in connection with its acquisition of SendGrid, Inc. in an all-stock transaction valued at approximately $3 billion
  • Investors in Signal Sciences Corp. in connection with Signal Sciences’ $775 million sale to Fastly, Inc.
  • Foundation Medicine, Inc. in connection with its merger with Roche at an enterprise valuation of $5.3 billion
  • PTC Inc. in connection with its strategic partnership with Rockwell Automation, Inc. and securing a $1 billion equity investment
  • Evergreen Coast Capital in connection with its $1.6 billion acquisition of Gigamon Inc.*
  • Hewlett Packard Enterprise Company in connection with the $7 billion spin-off and merger of its Enterprise Services business with Computer Sciences Corporation to form DXC Technology Company*
  • Hologic, Inc. in connection with the sale of its blood screening business for $1.85 billion to Grifols S.A.*
  • Diamond Resorts International, Inc. in connection with its $2.2 billion sale to Apollo Management*
  • Marriott International, Inc. in its $12.2 billion acquisition of Starwood Hotels & Resorts Worldwide, Inc.*
  • Shire plc in connection with its abandoned $54.8 billion sale to AbbVie Inc.*
  • Bertelsmann SE & Co. KGaA and Random House in connection with the merger of Random House with Penguin Publishing House*
  • Dalian Wanda Group in connection with its $2.6 billion acquisition of AMC Entertainment Holdings, Inc.*

*Denotes experience prior to joining Goodwin.

Michael represents the most sophisticated and well-known asset managers in the world, including top-tier private equity and venture capital funds, hedge funds, family offices and multi-strategy investors, as well as their respective portfolio companies, in acquisitions, sales, and financings.

  • Pear Therapeutics, Inc. in connection with its business combination with SPAC Thimble Point Acquisition Corp. in a transaction valued at approximately $1.6 billion
  • Markforged, Inc. in connection with its business combination with SPAC one in a transaction valued at approximately $2.1 billion
  • Alpha Healthcare Acquisition Corp. in connection with its business combination with Humacyte, Inc. in a transaction valued at approximately $1.1 billion
  • Cano Health, LLC in connection with its business combination with SPAC Jaws Acquisition Corp in a transaction valued at approximately $5.9 billion  
  • Existing investors in Billtrust in connection with Billtrust’s business combination with SPAC South Mountain Merger Corporation in a transaction valued at approximately $2.5 billion
  • Immatics N.V. in connection with its business combination with SPAC Arya Sciences Acquisition Corp. in a transaction valued at approximately $1 billion
  • Investors in connection with Ginkgo Bioworks, Inc.’s business combination with SPAC Soaring Eagle Acquisition Corp. in a transaction valued at approximately $17.5 billion
  • Investors in connection with POINT Biopharma Inc.’s business combination with SPAC Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I in a transaction valued at approximately $924 million

Michael is active in the firm’s pro bono efforts with local entrepreneurs through the Neighborhood Business Initiative and Start Small Think Big. In his free time, Michael is also an avid supporter of the local music and arts communities.

Credentials

Education

JD2011

Harvard Law School

(cum laude)

MSAccounting2008

University of Florida

(Beta Alpha Psi)

BSAccounting2006

University of Florida

Admissions

Bars

  • Florida
  • New York

Recognition & Awards

During law school, Michael served on the executive boards of the Harvard Business Law Review and the Harvard Journal of Law & Public Policy.

Michael was recognized in the Financial Times Innovative Lawyers 2019: Enabling Business Growth and Transformation deal awards.

Publications

Michael is a frequent speaker on matters related to corporate governance, mergers and acquisitions, SPACs, corporate finance and securities law. His recent speaking engagements and publications include: